PMS and PMDD: Understanding the Premenstrual Emotional Storm
Daily records and assessment help distinguish PMS, PMDD and premenstrual worsening of an existing condition.

In this article
“Every month there are a few days when I feel like a different person—I cry over small things, snap at the people closest to me, and late at night replay things I said with regret. Then my period starts, and it is as if nothing happened.” I have received this quiet, precise description many times through our inbox. It appears not only in direct messages, but is repeated by thousands of women in Instagram and TikTok's #PMDD communities; on Xiaohongshu, discussions of “managing premenstrual emotions” are everywhere.
3–8%
PMDD
(pre-menstrual dysphoric disorder) prevalence among menstruating people [Academic]; milder PMS affects a broader population. This is not niche “oversensitivity,” but a cyclical health issue that has long been underestimated.
This article aims to replace the shame of “Am I just bad-tempered?” with understanding of “What exactly is my body experiencing?” Because understanding is the first step toward care and self-help.
Why can #PMDD form such large communities on Instagram and TikTok? Because so many women first encounter a word there and suddenly realize “I am not alone, and I am not just bad-tempered.” For a long time, premenstrual emotions were lightly dismissed as “being dramatic,” “oversensitive,” or “a sign of approaching menopause,” and even used by partners and family as a reason to refuse communication. When a real, medically definable condition is long confined to the drawer labeled “personality,” silence becomes the most common response. The intense activity in these communities shows exactly this: many people have waited a long time to have their experience seriously explained. The widespread discussion of “managing premenstrual emotions” on Chinese social media echoes the same need—people are not looking for an excuse; they are looking for an answer.
One. First correct a misconception: this is not a “personality problem”

Actual view of the Taal Volcano lake area; unrelated to the medical evidence in this article.
Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) both essentially belong to premenstrual disorders—a group of symptoms that recur during the luteal phase of the menstrual cycle (after ovulation and before menstruation) and ease within a few days after menstruation begins. At their core, they are not “you are not good enough,” but an abnormal sensitivity in the brain to normal hormonal fluctuations.
The key mechanism is this: the ovaries regularly release estrogen and progesterone over each cycle. One metabolite of progesterone—allopregnanolone—is a neuroactive steroid that can act on the central GABA system. Most women do not notice these fluctuations, but for people with PMDD the same fluctuations can trigger marked emotional symptoms. In other words, the problem is not abnormally “high or low” hormone levels, but a different brain response threshold to hormonal change. That is why simply “balancing the endocrine system” often does not work, whereas interventions targeting neurotransmitters such as serotonin often do.
There is another commonly misunderstood point: many women intuitively think “my estrogen is low” or “something is wrong with my ovaries,” then seek “hormone supplements” or “ovarian care.” Yet studies repeatedly show that hormone levels in women with PMDD are mostly within the normal range—the abnormality lies in the brain's response to fluctuations, rather than the absolute hormone values. This also explains why “hormone balancing” often fails while drugs such as SSRIs that regulate neurotransmitters can work quickly. Understanding this can prevent many detours and unnecessary expenses. Genetic tendencies, gut-microbiome differences, magnesium or calcium deficiency, and even mild immune inflammation may all contribute to this sensitive pathway, but the most widely accepted core remains the interaction between neurosteroids and the serotonin system.
This also explains a phrase that recurs throughout the article: “cycle-locked.” The most tormenting feature of PMDD is not the symptoms themselves, but their predictability: you know those days are coming, yet feel as though you are watching yourself lose control from behind glass. When others misunderstand it as “here you go again,” the resulting isolation can far exceed the physical discomfort. Understanding the mechanism first shifts responsibility from “personality” back to “physiology and neurology,” allowing the person affected to say with confidence: it is not my fault; it is a condition that can be addressed.
Remember this in one sentence
PMS/PMDD symptoms are “cycle-locked”; they are not a personality flaw and cannot be cured by “just looking on the bright side.” They have a clear physiological and neurological basis, and therefore clear medical approaches.
Two. PMS and PMDD: two ends of the same river
Many people think of PMDD as “severe PMS,” which is fair, but there is a clear dividing line between them—severity and functional impairment. Simply put: PMS makes you uncomfortable; PMDD makes it “impossible to function normally” on those days.
- PMS (premenstrual syndrome): [Academic] Around 13%–18% of women of reproductive age in the United States are affected, with bloating, breast tenderness, headache, mood swings, irritability, and similar symptoms, most often mild to moderate.
- PMDD (premenstrual dysphoric disorder): A severe form of PMS, with [Academic] prevalence of around 2%–6% (some epidemiological estimates have a higher upper bound, and global PMDD estimates may reach around 18%). It is formally classified in [Academic] DSM-5-TR (2022) as a depressive disorder, meaning symptoms are severe enough to significantly impair work, social life, and relationships.
One phenomenon worth noting is that PMS is so common yet has long remained at the edge of medical attention. On one hand, it is “not life-threatening enough” and assumed to be part of what women should “just put up with”; on the other, its symptoms span mind and body, fitting neither the image of a typical medical illness nor a typical mental illness, and are easily passed back and forth. PMDD was formally included in diagnostic systems only in recent decades—which means many women now in their thirties and forties grew up hardly ever hearing the word “PMDD,” and naturally never connected their severe premenstrual breakdowns to a treatable disorder. The gap in awareness is itself a cost and a reminder: knowing “it has a name” is often the first step to getting help.
One important distinction
PMS is not a psychiatric diagnosis; PMDD is. This distinction matters because it determines which specialty to consult and how to approach care—lifestyle and comorbidity management, or standardized treatment in collaboration between mental-health and gynecology clinicians.
Because the boundary is blurry, PMDD has also long been underestimated and missed. Its symptoms fall into the gap between “gynecology” and “mental health”: a gynecologist may focus more on bleeding and cycles, while a mental-health clinician may not proactively ask “are the symptoms related to your period?” As a result, many women travel from place to place wondering “am I depressed?” without anyone suggesting they use a cycle-tracking chart. The article's repeated emphasis on “tracking” is intended to transform symptoms from a vague “I am not feeling well” into a comparable “luteal-phase-locked pattern,” reducing missed diagnoses. More complicated still, PMDD often coexists with depression or anxiety or is layered onto a pre-existing mood disorder. Distinguishing which came first and which is the primary driver itself requires professional assessment, rather than self-diagnosis.
Three. How can you tell if it might be PMDD? Look at timing and the checklist

Actual view of Kawasan Falls, Cebu; unrelated to the medical evidence in this article.
PMDD diagnosis does not depend on “how I feel it is,” but on prospective tracking. This is especially easy to overlook: studies repeatedly warn that retrospective recall greatly overestimates the cyclical nature of symptoms—we are more likely to remember “that time I blew up” and forget “actually, most of the month was fine.” Thus, the diagnostic gold standard is daily symptom tracking for at least two consecutive menstrual cycles.
A commonly used clinical tool is the Daily Record of Severity of Problems (DRSP), essentially a daily rating sheet: score emotional, physical, and functional symptoms each day across two consecutive cycles. Its value is turning “I feel awful around those days” into a set of comparable data. If you cannot access a validated scale, you can keep your own record—the four key elements are: ① dates and the start/end of menstruation; ② emotional symptoms (irritability, tearfulness, anxiety, low mood); ③ physical symptoms (tenderness, headache, fatigue, appetite); ④ functional impact (effects on work and relationships). If your records are continuous and honest, the pattern usually emerges after two or three months. A special reminder: whether you are truly “fine” during the week after menstruation is the most important item on the entire chart; mark it separately.
The core DSM-5-TR criteria [Academic] can be condensed into three sentences:
- In the final week before menstruation, ≥5 symptoms occur, with at least 1 core emotional symptom (marked mood instability, irritability/anger, depression/hopelessness, or anxiety/tension);
- Symptoms clearly improve within a few days after menstruation begins and largely disappear during the week after menstruation (there is a “symptom-free interval”);
- This pattern occurs in most cycles over the past year and causes significant distress or functional impairment.
The most important distinguishing point
“Are you mostly fine during the week after your period?”—this “symptom-free interval” is PMDD's identifying feature. If a person's low mood and anxiety are roughly the same all month and only become worse before menstruation, it is more likely that
an existing mood disorder is amplified premenstrually
rather than PMDD. The two conditions have entirely different treatment approaches: the former may need continuous treatment, while the latter may be managed sufficiently with a “luteal-phase-only” approach.
Four. The confusion people 40+ most need to sort out: PMDD, perimenopause, or “an existing mood problem”

Actual view of a Philippine waterfall; unrelated to the medical evidence in this article.
For readers over 40, this can become particularly confusing because three lines often intertwine:
- PMDD: strictly linked to the luteal phase, with a clear symptom-free interval after menstruation;
- Perimenopausal mood fluctuations: [Academic] available evidence indicates that PMS symptoms may worsen under stress or during perimenopause, and in some perimenopausal women symptoms may even continue after menstruation. The mood changes are often more “diffuse,” with less distinct cycle boundaries, and are commonly accompanied by typical perimenopausal signs such as hot flashes and sleep changes;
- A mood disorder with premenstrual exacerbation: depression or anxiety exists in its own right, is amplified before menstruation, and has a low-mood baseline throughout the month.
Conflating these conditions has consequences: using a “luteal-phase-only” approach for perimenopause as if it were PMDD may not work; dismissing PMDD as “normal menopausal fluctuation” may mean missing treatment that could markedly improve quality of life. The key to distinguishing them is still tracking—chart mood, physical symptoms, and menstrual dates on the same page continuously for two or three months; the different patterns will become visible.
One more pitfall that readers 40+ may easily hit: many think “I am this age and my periods are irregular, so feeling emotional on those days is normal.” Perimenopause can indeed amplify mood fluctuations, but “normal” does not mean “nothing needs to be done.” The key question remains: are low mood and irritability strictly limited to the days before menstruation and gone after it? If the answer is “more or less,” PMDD is less likely; if “the whole month is gray, and before my period it gets darker,” an independent mood issue is more likely and needs another care pathway. Grouping both very different situations under the four words “you are getting older” delays care twice over.
A reminder for readers 40+
After age 40, menstrual cycles themselves may become irregular as perimenopause begins, further blurring the boundary of the “luteal phase.” If the relationship between mood symptoms and menstruation becomes hard to discern, that is an even stronger reason to bring your records to a clinician rather than label yourself based on feelings.
Five. Treatment map: from lifestyle to appropriate medication

Forest stream in Bukidnon; an actual location unrelated to the medical evidence in this article.
The good news is that PMDD is one of the premenstrual disorders with the strongest evidence base and clearest treatment options. Care is tiered, individualized, and multimodal.
There are pitfalls amid the many suggestions, however. Online, “chasteberry,” “evening primrose oil,” and various “detox and wellness” products are often recommended as PMDD remedies, though some have weak or no high-quality research support. They may help a few people, but cannot replace the evidence-based options discussed above, and should not be assumed safe for long-term use simply because they are “natural.” A simple way to assess a recommendation is to ask: is it supported by randomized controlled studies, and is it an option clinicians discuss within a standard care pathway? “Try it” should always come after “consult a clinician.” One more point must be clear: severe PMDD can involve thoughts of self-harm. Any such signal warrants immediate professional help, rather than trying to tough it out with “wellness balancing.”
First line: medication targeting emotional symptoms
SSRIs (selective serotonin reuptake inhibitors) are first-line for PMDD emotional symptoms [Academic]. They have a special feature: in PMDD, SSRIs often act quickly (in days rather than weeks), and can be taken using “luteal-phase-only dosing”—only in the second half of each cycle, stopping during the rest of the month. This is unusual in other depressive disorders and reflects PMDD's distinctive neurological mechanism. The choice of medicine, continuous versus intermittent dosing, and dose must be decided by a clinician based on contraindications and individual circumstances.
Hormonal options
Combined oral contraceptives containing certain progestogens, such as drospirenone, are approved for PMDD in some countries and may be an option for those who also need contraception. A clinician must assess contraindications such as blood clots (particularly smoking, migraine history, age, and other factors); do not purchase and take them on your own.
About “treatment-resistant” cases
For the very small number of people with severe PMDD unresponsive to standard treatment, specialist guidelines mention considering more intensive interventions at the specialty level (such as ovarian-function suppression, or surgical options in extreme cases). These are specialist decisions, never routine care, and not something anyone should try independently; their existence simply shows that medicine has a complete “escalation ladder” for this condition and you do not have to give up if one step does not work. Appropriate referral and multidisciplinary collaboration are designed for people with severe disease.
Non-medication approaches
- Cognitive behavioral therapy (CBT): supported by research for improving PMS/PMDD symptoms [Academic] and offers long-term benefits for emotional coping;
- Calcium supplementation: daily supplementation of around 1000–1200 milligrams may reduce PMS symptoms according to some evidence [Academic];
- Regular exercise and sleep, reducing caffeine and high-salt/high-sugar foods: evidence levels vary, but these are broadly recommended as basic care;
- Tracking and anticipatory planning: knowing “which days are harder” and reducing major decisions and high-conflict situations in advance can itself provide a buffer.
The takeaway: do not self-diagnose, but do not simply endure
You can use this article's “three-sentence criteria” for self-screening, but
diagnosis must be made by a clinician
—and ideally assessed collaboratively by gynecology and mental-health specialists. Bringing two or three months of records to an appointment is much more efficient than simply saying “I get bad-tempered before my period.” The goal of treatment is not to eliminate the menstrual cycle, but to let you live well during those days too. The right to be informed and shared decisions are always more reliable than a viral “balancing remedy.”
Six. Four questions readers ask most often
Q1: Am I “being oversensitive”? Why do I feel so bad when others are fine?
You are not oversensitive; your threshold differs. As described above, PMDD is an abnormal brain response to normal hormonal fluctuations, unrelated to “personality” or “self-cultivation.” Treating it as a condition that medicine can understand and improve is the first step toward letting go of shame.
Q2: Can I buy birth-control pills myself to adjust things?
Not recommended. Hormonal options require assessing multiple contraindications, including clots, migraine, smoking, and age; suitability for PMDD varies greatly among preparations. They require prescription and monitoring by a clinician. Self-medication may be ineffective and may cause risk.
Q3: My family always says “here you go again.” How can I help them understand?
Showing them this article or your symptom record is more effective than explaining a hundred times. The core message is just one sentence: this is not an emotion directed at anyone, but a cyclical physiological and neurological response. It can be treated and deserves to be taken seriously.
Q4: I am already in my 40s, and my periods are irregular. Should I still pay attention to PMDD?
Even more so, because this is a period when confusion is common. Perimenopause itself changes mood and sleep, and if unrecognized PMDD is layered on top, the experience becomes much worse. Using “two or three months of tracking” to clarify the boundary between them can bring more precise support during the transition, rather than attributing all discomfort vaguely to “getting older.”
Q5: When should I start tracking, and what should I use?
You can start “today”—no need to wait until next month. Many free period-tracking apps include mood ratings; pen and paper are completely adequate too. The important thing is not how sophisticated the tool is, but continuity and honesty. Keep tracking through at least two complete cycles before drawing a conclusion; a single month's fluctuations may be affected by occasional travel, staying up late, a cold, and other factors, while two cycles can reveal the true “pattern.” Bring the chart to a consultation and a clinician can quickly determine whether it is PMS, PMDD, or something else.
Seven. In closing

Landmark in Vigan's historic district; actual view unrelated to the medical evidence in this article.
The reader at the beginning said, “I feel like a different person on those days.” I want to tell her, and everyone who counts days on a calendar anxiously waiting for “that self” to come back: you have not changed; your body is sending a signal according to its own rhythm. PMDD is not a flaw in you, but a real condition that can be noticed, named, and managed. The power of “being named” is often underestimated: once a form of distress has a name, it changes from “what is wrong with me?” into “a condition that can be addressed”—and the latter is what can truly take you into a clinic and in front of a clinician.
The millions of stories on Instagram and TikTok, and the widespread discussion on Xiaohongshu, are fundamentally all the same thing: we are finally beginning to speak seriously about what happens during those days. I hope this article helps you feel less self-blame and more confidence the next time you face them—knowing what to look for, what to ask, and whom to find. You deserve to be taken seriously and to receive effective help.
Quick-reference literature for clinicians
- DSM-5-TR (2022): Classifies PMDD as a depressive disorder (code 625.4), defining key criteria of “≥5 symptoms in the final week before menstruation, including ≥1 core emotional symptom; improvement after menstruation; a symptom-free interval; and functional impairment.”
- ACOG Clinical Practice Guideline, Management of Premenstrual Disorders (2023): Provides a clinical management framework for premenstrual disorders and emphasizes prospective symptom tracking and tiered treatment.
- Marjoribanks J et al., Cochrane systematic review (2013): Confirms that SSRIs are effective for emotional and physical PMS symptoms, among interventions with the highest level of evidence.
- Shah NR et al., Obstet Gynecol (2008), SSRI meta-analysis: Pooled randomized controlled trials supporting SSRI use for PMS/PMDD; luteal-phase-only dosing can also be effective.
- Lopez LM et al., Cochrane (2012): Assessed combined oral contraceptives containing drospirenone for PMS, providing an evidence basis for hormonal options.
- IAPMD (International Association for Premenstrual Disorders): A patient and clinical resource organization that continually updates diagnostic tools (such as the Daily Record of Severity of Problems) and consensus, emphasizing that “prospective tracking for ≥2 cycles” is foundational to diagnosis.
Note: These are directional references. Evidence levels vary among studies (Cochrane reviews are high-level; some nutrition/supplement evidence is low-level). Specific care should follow current guidelines and individual circumstances; studies with different designs (guidelines/systematic reviews/cross-sectional research) cannot automatically be generalized.
Supplementary research and evidence boundaries:
Diagnostic and treatment frameworks refer to ACOG 2023 Clinical Practice Guideline No. 7, DSM-5-TR (PMDD diagnostic criteria), and Cochrane systematic reviews on SSRIs/treatment of premenstrual symptoms. Prevalence varies with screening tools, diagnostic thresholds, and sample sources; discussion volume on social platforms cannot replace epidemiological surveys. Anyone with thoughts of self-harm or substantial functional impairment should receive a collaborative assessment from mental-health and gynecology professionals as a priority.
Disclaimer:
This is health education compiled from public guidelines, systematic reviews, and platform-trend data to help readers recognize symptoms and consider seeking care;
it is not an individualized diagnosis or treatment recommendation
. Decisions on medication, diagnosis, and care approach must be made together with your treating clinician (ideally in collaboration between gynecology and mental-health professionals) and follow the latest guidelines in your country/region. If you have thoughts of self-harm or symptoms seriously affecting your life, seek professional help promptly.
Read the source material
The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.
A good question starts a conversation.
Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.


